Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
52
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Benjamson Philip | SENIOR VICE PRESIDENT & COO | 1 | $0 | $0 | 2023-03-18 |
| Pereira Heather | SENIOR VICE PRESIDENT & CFO | 1 | $0 | $0 | 2023-03-18 |
| Geiger Stephen R. | VP & CAO | 1 | $0 | $0 | 2023-03-18 |
| Leer Jeffrey C. | PRESIDENT AND CEO | 1 | $0 | $0 | 2023-03-18 |
| FRAICHE DONNA D. | Director | 1 | $0 | $0 | 2023-03-18 |
| GILMORE BARBARA D. | Director | 2 | $0 | $0 | 2023-03-18 |
| PORTNOY ADAM D. | Director | 2 | $29.31M | $0 | 2023-03-18 |
| GANS BRUCE M. | Director | 1 | $0 | $0 | 2023-03-18 |
| CLARK JENNIFER B | Director | 1 | $0 | $0 | 2023-03-18 |
| MARTIN GERARD M. | Director | 1 | $0 | $0 | 2023-03-18 |
| Ginsburg Geoffrey S | Director | 5 | $0 | $0 | 2017-10-03 |
| Uppaluri Renuka | Senior VP, Global R&D | 20 | $0 | $0 | 2017-10-03 |
| Gladwell Mark | Senior VP, Global Operations | 47 | $0 | $2.17M | 2017-10-03 |
| Powers Gregg J | Director | 7 | $0 | $0 | 2017-10-03 |
| Wygant Jonathan | VP, Controller, CAO | 5 | $0 | $0 | 2017-10-03 |
| McKillop Thomas | Director | 7 | $0 | $0 | 2017-10-03 |
| Guerdan Melissa | VP, Global Quality & Reg. | 47 | $0 | $1.58M | 2017-10-03 |
| Cramp Daniella | Pres., Chronic Care | 44 | $0 | $0 | 2017-10-03 |
| Malkani Sanjay | Pres., Toxicology | 54 | $0 | $3.77M | 2017-10-03 |
| Nawana Namal | Chief Operating Officer | 38 | $0 | $0 | 2017-10-03 |
| Hinrichs James F. | Executive VP, CFO | 17 | $1.39M | $0 | 2017-10-03 |
| Roosevelt James Jr. | Director | 8 | $0 | $0 | 2017-10-03 |
| Chiniara Ellen | General Counsel and Secretary | 46 | $0 | $0 | 2017-10-03 |
| Hargadon Robert Bernard | VP, Global Human Resources | 30 | $39.0K | $0 | 2017-10-03 |
| Pelossof Avi | Pres., Infectious Disease | 44 | $0 | $0 | 2017-10-03 |
| MARKISON BRIAN A | Director | 7 | $0 | $0 | 2017-10-03 |
| BRIDGEN JOHN | VP, Strategic Business Develop | 59 | $0 | $5.43M | 2017-10-03 |
| LEVY JOHN F | Director | 13 | $0 | $0 | 2017-10-03 |
| QUELCH JOHN | Director | 14 | $0 | $475.0K | 2017-10-03 |
| GOLDBERG CAROL R | Director | 16 | $0 | $8.7K | 2017-10-03 |
| Bjorklund Hakan | Director | 3 | $0 | $0 | 2016-11-15 |
| Flakne Carla | VP, Chief Accounting Officer | 24 | $0 | $1.68M | 2016-02-16 |
| Teitel Dave | Chief Financial Officer | 11 | $0 | $668.0K | 2015-02-28 |
| Keyes Craig | Global Pres, Health Info. Solu | 3 | $0 | $0 | 2014-02-28 |
| Lindner Nigel | VP, R&D | 1 | $0 | $0 | 2014-02-27 |
| O'Rourke John | Chief Information Officer | 2 | $0 | $0 | 2014-02-27 |
| EYLENBOSCH HILDE | President, Alere International | 5 | $0 | $54.3K | 2014-02-27 |
| HEMPEL PAUL T | SVP Ethics & Compliance | 15 | $0 | $346.6K | 2014-02-27 |
| Benjamin Regina M. | Director | 2 | $0 | $0 | 2013-12-31 |
| SCOTT DAVID | Chief Scientific Officer | 5 | $0 | $0 | 2013-12-16 |
| MCALEER JEROME F | VP, Research & Development | 7 | $0 | $0 | 2013-12-12 |
| Torchilin Kate | VP, Connected Health | 6 | $0 | $288.3K | 2013-12-11 |
| ZWANZIGER RON | Chairman, CEO & President | 6 | $0 | $0 | 2013-11-01 |
| MACMILLAN STEPHEN P | Director | 2 | $0 | $0 | 2013-10-31 |
| Cotton Michael Lester | Global Pres, Health Mgmt | 8 | $0 | $649.0K | 2013-08-05 |
| Post Jim | President, Alere NA | 4 | $0 | $40.9K | 2013-03-07 |
| Walton David | President, Asia-Pacific | 2 | $0 | $0 | 2013-02-07 |
| Hart Emanuel | President, LAmARCIS | 3 | $0 | $0 | 2013-02-07 |
| Russell Jon | VP, Finance | 1 | $0 | $0 | 2013-02-07 |
| DITULLIO ROBERT | VP, Global Reg and Clinical | 1 | $0 | $0 | 2013-02-07 |
| TOOHEY DAVID | President, Intl Bus. Operation | 3 | $0 | $2.8K | 2012-08-14 |
| Underwood Thomas | CEO, Alere Health LLC | 3 | $0 | $19.5K | 2012-02-16 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Leer Jeffrey C. | PRESIDENT AND CEO | U Tender | 2023-03-18 | 2023-03-20 | 433,363 | — | $0 | 0 | SEC↗ |
| CLARK JENNIFER B | Director | U Tender | 2023-03-18 | 2023-03-20 | 122,573 | — | $0 | 0 | SEC↗ |
| Geiger Stephen R. | VP & CAO | U Tender | 2023-03-18 | 2023-03-20 | 68,694 | — | $0 | 0 | SEC↗ |
| Benjamson Philip | SENIOR VICE PRESIDENT & COO | U Tender | 2023-03-18 | 2023-03-20 | 46,435 | — | $0 | 0 | SEC↗ |
| GILMORE BARBARA D. | Director | U Tender | 2023-03-18 | 2023-03-20 | 43,075 | — | $0 | 0 | SEC↗ |
| GILMORE BARBARA D. | Director | U Tender | 2023-03-18 | 2023-03-20 | 1,000 | — | $0 | 0 | SEC↗ |
| GANS BRUCE M. | Director | U Tender | 2023-03-18 | 2023-03-20 | 43,194 | — | $0 | 0 | SEC↗ |
| FRAICHE DONNA D. | Director | U Tender | 2023-03-18 | 2023-03-20 | 40,100 | — | $0 | 0 | SEC↗ |
| MARTIN GERARD M. | Director | U Tender | 2023-03-18 | 2023-03-20 | 60,451 | — | $0 | 0 | SEC↗ |
| Pereira Heather | SENIOR VICE PRESIDENT & CFO | U Tender | 2023-03-18 | 2023-03-20 | 46,476 | — | $0 | 0 | SEC↗ |
| PORTNOY ADAM D. | Director | P Buy | 2023-03-18 | 2023-03-20 | 22,375,687 | $1.31 | $29.31M | 22,375,687 | SEC↗ |
| PORTNOY ADAM D. | Director | U Tender | 2023-03-18 | 2023-03-20 | 57,332 | $1.31 | $75.1K | 0 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Development | D To issuer deriv | 2017-10-03 | 2017-10-03 | 11,788 | — | $0 | 0 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Development | D To issuer deriv | 2017-10-03 | 2017-10-03 | 750 | — | $0 | 0 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Development | D To issuer deriv | 2017-10-03 | 2017-10-03 | 16,324 | — | $0 | 0 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Development | D To issuer deriv | 2017-10-03 | 2017-10-03 | 2,500 | — | $0 | 0 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Development | D To issuer deriv | 2017-10-03 | 2017-10-03 | 35,000 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 1,500 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 19,470 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 11,788 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 975 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,250 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 35,000 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 10,000 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer deriv | 2017-10-03 | 2017-10-03 | 8,331 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 25,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 2,500 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 14,709 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 40,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 50,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 10,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 45,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 15,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 1,500 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 15,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 19,470 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer deriv | 2017-10-03 | 2017-10-03 | 2,291 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer deriv | 2017-10-03 | 2017-10-03 | 4,000 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer deriv | 2017-10-03 | 2017-10-03 | 7,737 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer deriv | 2017-10-03 | 2017-10-03 | 35,000 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer deriv | 2017-10-03 | 2017-10-03 | 500 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer deriv | 2017-10-03 | 2017-10-03 | 4,750 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer deriv | 2017-10-03 | 2017-10-03 | 2,500 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer deriv | 2017-10-03 | 2017-10-03 | 16,324 | — | $0 | 0 | SEC↗ |
| GOLDBERG CAROL R | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 41,685 | — | $0 | 0 | SEC↗ |
| GOLDBERG CAROL R | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 33,515 | — | $0 | 0 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | D To issuer deriv | 2017-10-03 | 2017-10-03 | 6,063 | — | $0 | 0 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | D To issuer deriv | 2017-10-03 | 2017-10-03 | 35,000 | — | $0 | 0 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,148 | — | $0 | 0 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | D To issuer deriv | 2017-10-03 | 2017-10-03 | 1,250 | — | $0 | 0 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | D To issuer deriv | 2017-10-03 | 2017-10-03 | 19,470 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | D To issuer deriv | 2017-10-03 | 2017-10-03 | 16,324 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | D To issuer deriv | 2017-10-03 | 2017-10-03 | 1,250 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | D To issuer deriv | 2017-10-03 | 2017-10-03 | 9,600 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | D To issuer deriv | 2017-10-03 | 2017-10-03 | 800 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | D To issuer deriv | 2017-10-03 | 2017-10-03 | 35,000 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | D To issuer deriv | 2017-10-03 | 2017-10-03 | 20,000 | — | $0 | 0 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | D To issuer deriv | 2017-10-03 | 2017-10-03 | 44,350 | — | $0 | 0 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | D To issuer deriv | 2017-10-03 | 2017-10-03 | 108,118 | — | $0 | 0 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | D To issuer deriv | 2017-10-03 | 2017-10-03 | 250,000 | — | $0 | 0 | SEC↗ |
| LEVY JOHN F | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 49,156 | — | $0 | 0 | SEC↗ |
| LEVY JOHN F | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 56,274 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 2,500 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 10,000 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 15,000 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 3,375 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 19,470 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 6,133 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 3,900 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 10,000 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 25,000 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 25,000 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 45,000 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 16,040 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer deriv | 2017-10-03 | 2017-10-03 | 7,500 | — | $0 | 0 | SEC↗ |
| MARKISON BRIAN A | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 53,756 | — | $0 | 0 | SEC↗ |
| McKillop Thomas | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 53,756 | — | $0 | 0 | SEC↗ |
| Nawana Namal | Chief Executive Officer | D To issuer deriv | 2017-10-03 | 2017-10-03 | 23,077 | — | $0 | 0 | SEC↗ |
| Nawana Namal | Chief Executive Officer | D To issuer deriv | 2017-10-03 | 2017-10-03 | 200,000 | — | $0 | 0 | SEC↗ |
| Nawana Namal | Chief Executive Officer | D To issuer deriv | 2017-10-03 | 2017-10-03 | 300,000 | — | $0 | 0 | SEC↗ |
| Nawana Namal | Chief Executive Officer | D To issuer deriv | 2017-10-03 | 2017-10-03 | 100,000 | — | $0 | 0 | SEC↗ |
| Nawana Namal | Chief Executive Officer | D To issuer deriv | 2017-10-03 | 2017-10-03 | 50,000 | — | $0 | 0 | SEC↗ |
| Nawana Namal | Chief Executive Officer | D To issuer deriv | 2017-10-03 | 2017-10-03 | 111,041 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 1,125 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 19,470 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 25,000 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 45,000 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 50,000 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 20,000 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 14,081 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 14,250 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 5,000 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 10,000 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer deriv | 2017-10-03 | 2017-10-03 | 2,500 | — | $0 | 0 | SEC↗ |
| Powers Gregg J | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 39,820 | — | $0 | 0 | SEC↗ |
| QUELCH JOHN | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 56,274 | — | $0 | 0 | SEC↗ |
| QUELCH JOHN | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 41,336 | — | $0 | 0 | SEC↗ |
| Roosevelt James Jr. | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 49,156 | — | $0 | 0 | SEC↗ |
| Roosevelt James Jr. | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 8,000 | — | $0 | 0 | SEC↗ |
| Roosevelt James Jr. | Director | D To issuer deriv | 2017-10-03 | 2017-10-03 | 41,685 | — | $0 | 0 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | D To issuer deriv | 2017-10-03 | 2017-10-03 | 22,991 | — | $0 | 0 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | D To issuer deriv | 2017-10-03 | 2017-10-03 | 75,000 | — | $0 | 0 | SEC↗ |
| Wygant Jonathan | VP, Controller, CAO | D To issuer deriv | 2017-10-03 | 2017-10-03 | 6,666 | — | $0 | 0 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Development | D To issuer | 2017-10-03 | 2017-10-03 | 20,646 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | D To issuer | 2017-10-03 | 2017-10-03 | 32,764 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer | 2017-10-03 | 2017-10-03 | 28,298 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | D To issuer | 2017-10-03 | 2017-10-03 | 275 | — | $0 | 0 | SEC↗ |
| Ginsburg Geoffrey S | Director | D To issuer | 2017-10-03 | 2017-10-03 | 5,530 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | D To issuer | 2017-10-03 | 2017-10-03 | 9,791 | — | $0 | 0 | SEC↗ |
| GOLDBERG CAROL R | Director | D To issuer | 2017-10-03 | 2017-10-03 | 40,614 | — | $0 | 0 | SEC↗ |
| GOLDBERG CAROL R | Director | D To issuer | 2017-10-03 | 2017-10-03 | 44,597 | — | $0 | 0 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | D To issuer | 2017-10-03 | 2017-10-03 | 16,385 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | D To issuer | 2017-10-03 | 2017-10-03 | 26,190 | — | $0 | 0 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | D To issuer | 2017-10-03 | 2017-10-03 | 72,230 | — | $0 | 0 | SEC↗ |
| LEVY JOHN F | Director | D To issuer | 2017-10-03 | 2017-10-03 | 172,223 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer | 2017-10-03 | 2017-10-03 | 28,757 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | D To issuer | 2017-10-03 | 2017-10-03 | 565 | — | $0 | 0 | SEC↗ |
| MARKISON BRIAN A | Director | D To issuer | 2017-10-03 | 2017-10-03 | 5,530 | — | $0 | 0 | SEC↗ |
| McKillop Thomas | Director | D To issuer | 2017-10-03 | 2017-10-03 | 5,530 | — | $0 | 0 | SEC↗ |
| Nawana Namal | Chief Executive Officer | D To issuer | 2017-10-03 | 2017-10-03 | 174,129 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | D To issuer | 2017-10-03 | 2017-10-03 | 26,005 | — | $0 | 0 | SEC↗ |
| Powers Gregg J | Director | D To issuer | 2017-10-03 | 2017-10-03 | 5,530 | — | $0 | 0 | SEC↗ |
| Powers Gregg J | Director | D To issuer | 2017-10-03 | 2017-10-03 | 46,000 | — | $0 | 0 | SEC↗ |
| QUELCH JOHN | Director | D To issuer | 2017-10-03 | 2017-10-03 | 26,651 | — | $0 | 0 | SEC↗ |
| Roosevelt James Jr. | Director | D To issuer | 2017-10-03 | 2017-10-03 | 9,974 | — | $0 | 0 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | D To issuer | 2017-10-03 | 2017-10-03 | 13,267 | — | $0 | 0 | SEC↗ |
| Wygant Jonathan | VP, Controller, CAO | D To issuer | 2017-10-03 | 2017-10-03 | 1,909 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise deriv | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 0 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | M Exercise deriv | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 0 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | M Exercise deriv | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 0 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | M Exercise deriv | 2017-08-31 | 2017-09-05 | 8,334 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise deriv | 2017-08-31 | 2017-09-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise deriv | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 0 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | M Exercise deriv | 2017-08-31 | 2017-09-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise deriv | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise deriv | 2017-08-31 | 2017-09-05 | 8,308 | — | $0 | 0 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise deriv | 2017-08-31 | 2017-09-05 | 1,692 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | F Tax w/h | 2017-08-31 | 2017-09-05 | 2,464 | $49.46 | $121.9K | 26,005 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 28,469 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | M Exercise | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 30,795 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | F Tax w/h | 2017-08-31 | 2017-09-05 | 2,038 | $49.46 | $100.8K | 28,757 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | F Tax w/h | 2017-08-31 | 2017-09-05 | 1,823 | $49.46 | $90.2K | 26,190 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | M Exercise | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 28,013 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | M Exercise | 2017-08-31 | 2017-09-05 | 8,334 | — | $0 | 19,516 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | F Tax w/h | 2017-08-31 | 2017-09-05 | 3,131 | $49.46 | $154.9K | 16,385 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | F Tax w/h | 2017-08-31 | 2017-09-05 | 2,350 | $49.46 | $116.2K | 9,791 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise | 2017-08-31 | 2017-09-05 | 5,000 | — | $0 | 12,141 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | F Tax w/h | 2017-08-31 | 2017-09-05 | 2,163 | $49.46 | $107.0K | 32,764 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 34,927 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | F Tax w/h | 2017-08-31 | 2017-09-05 | 1,879 | $49.46 | $92.9K | 20,646 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | M Exercise | 2017-08-31 | 2017-09-05 | 5,000 | — | $0 | 22,525 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | F Tax w/h | 2017-08-31 | 2017-09-05 | 1,663 | $49.46 | $82.3K | 28,298 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise | 2017-08-31 | 2017-09-05 | 1,692 | $48.14 | $81.5K | 29,961 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | F Tax w/h | 2017-08-31 | 2017-09-05 | 8,086 | $49.46 | $399.9K | 28,269 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise | 2017-08-31 | 2017-09-05 | 8,308 | $48.14 | $399.9K | 36,355 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | F Tax w/h | 2017-08-31 | 2017-09-05 | 2,505 | $49.46 | $123.9K | 28,047 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise | 2017-08-31 | 2017-09-05 | 6,667 | — | $0 | 30,552 | SEC↗ |
| Roosevelt James Jr. | Director | M Exercise deriv | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 0 | SEC↗ |
| QUELCH JOHN | Director | M Exercise deriv | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 0 | SEC↗ |
| Ginsburg Geoffrey S | Director | M Exercise deriv | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 0 | SEC↗ |
| Powers Gregg J | Director | M Exercise deriv | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 0 | SEC↗ |
| McKillop Thomas | Director | M Exercise deriv | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 0 | SEC↗ |
| MARKISON BRIAN A | Director | M Exercise deriv | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 0 | SEC↗ |
| LEVY JOHN F | Director | M Exercise deriv | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 0 | SEC↗ |
| GOLDBERG CAROL R | Director | M Exercise deriv | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 0 | SEC↗ |
| Roosevelt James Jr. | Director | M Exercise | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 9,974 | SEC↗ |
| QUELCH JOHN | Director | M Exercise | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 26,651 | SEC↗ |
| Ginsburg Geoffrey S | Director | M Exercise | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 5,530 | SEC↗ |
| Powers Gregg J | Director | M Exercise | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 5,530 | SEC↗ |
| McKillop Thomas | Director | M Exercise | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 5,530 | SEC↗ |
| MARKISON BRIAN A | Director | M Exercise | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 5,530 | SEC↗ |
| LEVY JOHN F | Director | M Exercise | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 163,655 | SEC↗ |
| GOLDBERG CAROL R | Director | M Exercise | 2017-06-30 | 2017-07-05 | 5,530 | — | $0 | 40,614 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | M Exercise deriv | 2017-04-06 | 2017-04-10 | 16,667 | — | $0 | 16,667 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | M Exercise | 2017-04-06 | 2017-04-10 | 16,667 | — | $0 | 72,230 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | M Exercise deriv | 2017-02-28 | 2017-03-02 | 6,667 | — | $0 | 6,667 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | F Tax w/h | 2017-02-28 | 2017-03-02 | 2,505 | $38.30 | $95.9K | 13,267 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | M Exercise | 2017-02-28 | 2017-03-02 | 6,667 | — | $0 | 15,772 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | M Exercise deriv | 2017-02-16 | 2017-02-21 | 5,663 | — | $0 | 11,324 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise deriv | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 14,470 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise deriv | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 14,470 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise deriv | 2017-02-16 | 2017-02-21 | 5,663 | — | $0 | 11,324 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | M Exercise deriv | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 14,470 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | M Exercise deriv | 2017-02-16 | 2017-02-21 | 5,663 | — | $0 | 11,324 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | M Exercise deriv | 2017-02-16 | 2017-02-21 | 13,842 | — | $0 | 27,683 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | M Exercise deriv | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 14,470 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Nawana Namal | Chief Executive Officer | M Exercise deriv | 2017-02-16 | 2017-02-21 | 47,188 | — | $0 | 94,374 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise deriv | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 14,470 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | M Exercise deriv | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,000 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | M Exercise deriv | 2017-02-16 | 2017-02-21 | 5,663 | — | $0 | 11,324 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 15,007 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | F Tax w/h | 2017-02-16 | 2017-02-21 | 939 | $40.40 | $37.9K | 14,068 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | F Tax w/h | 2017-02-16 | 2017-02-21 | 2,206 | $40.40 | $89.1K | 17,525 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | M Exercise | 2017-02-16 | 2017-02-21 | 5,663 | — | $0 | 19,731 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | F Tax w/h | 2017-02-16 | 2017-02-21 | 2,432 | $40.40 | $98.3K | 28,260 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 30,692 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | F Tax w/h | 2017-02-16 | 2017-02-21 | 811 | $40.40 | $32.8K | 23,456 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 24,267 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | F Tax w/h | 2017-02-16 | 2017-02-21 | 2,795 | $40.40 | $112.9K | 23,885 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 26,680 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | F Tax w/h | 2017-02-16 | 2017-02-21 | 939 | $40.40 | $37.9K | 19,444 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 20,383 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | F Tax w/h | 2017-02-16 | 2017-02-21 | 2,969 | $40.40 | $119.9K | 7,141 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 5,313 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | F Tax w/h | 2017-02-16 | 2017-02-21 | 866 | $40.40 | $35.0K | 4,447 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise | 2017-02-16 | 2017-02-21 | 5,663 | — | $0 | 10,110 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 7,702 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | F Tax w/h | 2017-02-16 | 2017-02-21 | 2,817 | $40.40 | $113.8K | 11,182 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | F Tax w/h | 2017-02-16 | 2017-02-21 | 939 | $40.40 | $37.9K | 6,763 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | M Exercise | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 13,999 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | M Exercise | 2017-02-16 | 2017-02-21 | 5,663 | — | $0 | 22,990 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | F Tax w/h | 2017-02-16 | 2017-02-21 | 683 | $40.40 | $27.6K | 17,327 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 18,010 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | F Tax w/h | 2017-02-16 | 2017-02-21 | 1,644 | $40.40 | $66.4K | 21,346 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | F Tax w/h | 2017-02-16 | 2017-02-21 | 5,260 | $40.40 | $212.5K | 55,563 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | M Exercise | 2017-02-16 | 2017-02-21 | 13,842 | — | $0 | 60,823 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | M Exercise | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 26,391 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 19,919 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | F Tax w/h | 2017-02-16 | 2017-02-21 | 764 | $40.40 | $30.9K | 19,155 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | F Tax w/h | 2017-02-16 | 2017-02-21 | 2,263 | $40.40 | $91.4K | 24,128 | SEC↗ |
| Nawana Namal | Chief Executive Officer | F Tax w/h | 2017-02-16 | 2017-02-21 | 18,576 | $40.40 | $750.5K | 147,654 | SEC↗ |
| Nawana Namal | Chief Executive Officer | M Exercise | 2017-02-16 | 2017-02-21 | 47,188 | — | $0 | 166,230 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | F Tax w/h | 2017-02-16 | 2017-02-21 | 2,741 | $40.40 | $110.7K | 21,802 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 18,231 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | F Tax w/h | 2017-02-16 | 2017-02-21 | 924 | $40.40 | $37.3K | 17,307 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise | 2017-02-16 | 2017-02-21 | 7,236 | — | $0 | 24,543 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | F Tax w/h | 2017-02-16 | 2017-02-21 | 2,230 | $40.40 | $90.1K | 9,105 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | M Exercise | 2017-02-16 | 2017-02-21 | 2,500 | — | $0 | 6,611 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | F Tax w/h | 2017-02-16 | 2017-02-21 | 939 | $40.40 | $37.9K | 5,672 | SEC↗ |
| Uppaluri Renuka | Senior VP, Global R&D | M Exercise | 2017-02-16 | 2017-02-21 | 5,663 | — | $0 | 11,335 | SEC↗ |
| Nawana Namal | Chief Executive Officer | M Exercise deriv | 2017-01-15 | 2017-06-16 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Nawana Namal | Chief Executive Officer | M Exercise | 2017-01-15 | 2017-06-16 | 50,000 | — | $0 | 169,042 | SEC↗ |
| Nawana Namal | Chief Executive Officer | F Tax w/h | 2017-01-15 | 2017-06-16 | 23,525 | $39.89 | $938.4K | 145,517 | SEC↗ |
| Wygant Jonathan | VP, Controller, CAO | M Exercise deriv | 2017-01-15 | 2017-01-17 | 3,334 | — | $0 | 6,666 | SEC↗ |
| Wygant Jonathan | VP, Controller, CAO | F Tax w/h | 2017-01-15 | 2017-01-17 | 1,425 | $39.89 | $56.8K | 1,909 | SEC↗ |
| Wygant Jonathan | VP, Controller, CAO | M Exercise | 2017-01-15 | 2017-01-17 | 3,334 | — | $0 | 3,334 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise deriv | 2016-12-30 | 2017-01-04 | 10,332 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise deriv | 2016-12-30 | 2017-01-04 | 9,668 | — | $0 | 0 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise deriv | 2016-12-30 | 2017-01-04 | 20,000 | — | $0 | 9,668 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise | 2016-12-30 | 2017-01-04 | 20,000 | $38.70 | $774.0K | 35,524 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | F Tax w/h | 2016-12-30 | 2017-01-04 | 10,263 | $38.96 | $399.8K | 15,731 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise | 2016-12-30 | 2017-01-04 | 10,332 | $38.70 | $399.8K | 25,994 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | F Tax w/h | 2016-12-30 | 2017-01-04 | 9,627 | $38.96 | $375.1K | 15,662 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | F Tax w/h | 2016-12-30 | 2017-01-04 | 19,903 | $39.00 | $776.2K | 15,621 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise | 2016-12-30 | 2017-01-04 | 9,668 | $38.70 | $374.2K | 25,289 | SEC↗ |
| Bjorklund Hakan | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| Ginsburg Geoffrey S | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| GOLDBERG CAROL R | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| LEVY JOHN F | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| MARKISON BRIAN A | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| McKillop Thomas | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| Powers Gregg J | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| QUELCH JOHN | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| Roosevelt James Jr. | Director | A Award deriv | 2016-11-15 | 2016-11-17 | 5,530 | — | $0 | 5,530 | SEC↗ |
| Nawana Namal | Chief Executive Officer | M Exercise deriv | 2016-10-31 | 2016-11-02 | 16,667 | — | $0 | 16,667 | SEC↗ |
| Nawana Namal | Chief Executive Officer | F Tax w/h | 2016-10-31 | 2016-11-02 | 7,850 | $44.68 | $350.7K | 119,042 | SEC↗ |
| Nawana Namal | Chief Executive Officer | M Exercise | 2016-10-31 | 2016-11-02 | 16,667 | — | $0 | 126,892 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise deriv | 2016-10-14 | 2016-10-18 | 5,000 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise deriv | 2016-10-14 | 2016-10-18 | 9,404 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise deriv | 2016-10-14 | 2016-10-18 | 7,096 | — | $0 | 0 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise deriv | 2016-10-14 | 2016-10-18 | 3,500 | — | $0 | 7,096 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise | 2016-10-14 | 2016-10-18 | 3,500 | $37.74 | $132.1K | 18,920 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | F Tax w/h | 2016-10-14 | 2016-10-18 | 4,393 | $42.95 | $188.7K | 21,529 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | F Tax w/h | 2016-10-14 | 2016-10-18 | 8,263 | $42.95 | $354.9K | 20,922 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise | 2016-10-14 | 2016-10-18 | 9,404 | $37.74 | $354.9K | 29,185 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise | 2016-10-14 | 2016-10-18 | 5,000 | $37.74 | $188.7K | 25,922 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | F Tax w/h | 2016-10-14 | 2016-10-18 | 6,235 | $42.95 | $267.8K | 19,781 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise | 2016-10-14 | 2016-10-18 | 7,096 | $37.74 | $267.8K | 26,016 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise deriv | 2016-10-03 | 2016-10-05 | 1,500 | — | $0 | 0 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | F Tax w/h | 2016-10-03 | 2016-10-05 | 1,337 | $43.24 | $57.8K | 2,813 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise | 2016-10-03 | 2016-10-05 | 1,500 | $34.40 | $51.6K | 4,150 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | M Exercise deriv | 2016-09-09 | 2016-09-13 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise deriv | 2016-09-09 | 2016-09-13 | 6,667 | — | $0 | 6,667 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise deriv | 2016-09-09 | 2016-09-13 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Guerdan Melissa | SVP, Global Quality & Reg. | M Exercise deriv | 2016-09-09 | 2016-09-13 | 8,333 | — | $0 | 8,334 | SEC↗ |
| Hargadon Robert Bernard | SVP, Global Human Resources | M Exercise deriv | 2016-09-09 | 2016-09-13 | 6,667 | — | $0 | 6,667 | SEC↗ |
| Hinrichs James F. | Executive VP, CFO | M Exercise deriv | 2016-09-09 | 2016-09-13 | 16,666 | — | $0 | 33,334 | SEC↗ |
| Pelossof Avi | GlobalPres, Infectious Disea | M Exercise deriv | 2016-09-09 | 2016-09-13 | 6,667 | — | $0 | 6,667 | SEC↗ |
| Cramp Daniella | Global Pres., Cardiometaboli | M Exercise deriv | 2016-09-09 | 2016-09-13 | 6,667 | — | $0 | 6,667 | SEC↗ |
| Malkani Sanjay | Global Pres., Toxicology | M Exercise deriv | 2016-09-09 | 2016-09-13 | 6,667 | — | $0 | 6,667 | SEC↗ |
| BRIDGEN JOHN | Sr VP, Business Develop | M Exercise | 2016-09-09 | 2016-09-13 | 5,000 | — | $0 | 12,507 | SEC↗ |
| Chiniara Ellen | GC, Chief Ethics Officer&Sec | M Exercise | 2016-09-09 | 2016-09-13 | 6,667 | — | $0 | 15,420 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | F Tax w/h | 2016-09-09 | 2016-09-13 | 2,350 | $42.34 | $99.5K | 2,650 | SEC↗ |
| Gladwell Mark | Senior VP, Global Operations | M Exercise | 2016-09-09 | 2016-09-13 | 5,000 | — | $0 | 5,000 | SEC↗ |